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Although reduced-intensity conditioning has become standard of care for patients with hematologic
malignancies undergoing allogeneic hematopoietic cell transplantation (HCT), the optimum regimen has yet
to be deﬁned, and may depend on pretransplantation patiente and/or disease-speciﬁc risk factors. We report
here results in 100 adults, ages 18 to 69, with high-risk hematologic malignancy who received conditioning
with ﬂudarabine, carmustine, melphalan, and rabbit antithymocyte globulin (FBM-A). Outcomes were
stratiﬁed using the disease risk index (DRI) as published by Armand et al. (Blood 2012;120:905-913). Median
age was 56, and patients were ineligible for standard myeloablative conditioning because of age, organ
dysfunction, or prior autologous HCT. Patients underwent transplantation for myeloid (acute myelogenous
leukemia, n ¼ 40; myelodysplastic syndrome, n ¼ 24; myeloﬁbrosis, n ¼ 13; other myeloid, n ¼ 2) or
lymphoid (acute lymphoblastic leukemia, n ¼ 8; non-Hodgkin lymphoma, n ¼ 8; Hodgkin lymphoma, n ¼ 4,
chronic lymphocytic leukemia, n ¼ 1) malignancy. Donors were related in 26 patients (22 matched, 4 mis-
matched at 1 antigen) and unrelated in 74 (mismatched at 1 or 2 HLA loci in 33); grafts were peripheral blood
stem cells in 97 patients, bone marrow in 2, and double cord in 1. According to the DRI, 68 patients were
classiﬁed as low (n ¼ 1) or intermediate risk (n ¼ 67), and 32 were classiﬁed as high (n ¼ 28) or very high risk
(n ¼ 4). With a median follow-up of surviving patients of 18 months, the Kaplan-Meier estimate of overall
survival at 2 years for patients in the low/intermediate risk group is 80%, compared with 66% in the high/very
high group (P ¼ .11). Two-year cumulative incidence of relapse and nonrelapse mortality in the low/inter-
mediate group are 9.9% and 15%, versus 25% and 19% in the high/very high group (respective P values .07 and
.81). The cumulative incidence of acute graft-versus-host (GVHD) grades III to IV at 100 days was 8.1%, and the
incidence of National Institutes of Healthedeﬁned moderate to severe chronic GVHD was 22% at 2 years. No
deaths were attributable to chronic GVHD. Survival was not inﬂuenced by age, hematopoietic comorbidity
index score, donor type, donor gender, or presence of mismatch. We conclude that FBM-A is an effective and
safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, interme-
diate-, or high-risk scores according to the DRI.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION considered suitable only for younger and generally healthy
For most individuals with high-risk or refractory hema-
tologic malignancies, the only option for cure is allogeneic
hematopoietic cell transplantation (HCT). The therapeutic
beneﬁt of allogeneic HCT ultimately derives from a graft-
versus-malignancy effect that is based on immunologic
disparity between the recipient and donor [1]. The strength
of the graft-versus-malignancy effect is widely variable and
depends on many factors, including the intrinsic immuno-
logic sensitivity of the malignancy, the degree of match
between the donor and recipient, and the bulk of disease at
transplantation. Until relatively recently, allogeneic HCT wasdgments on page 1174.
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13.05.001patients, primarily because of the perceived requirement for
pretransplantation ablative doses of chemotherapy and/or
radiation. In the last 2 decades, however, it has become clear
that lower intensity regimens, either nonmyeloablative or
reduced intensity (RIC), can be used successfully to condition
patients for allogeneic HCT, often with very low immediate
toxicity and good outcomes [2]. RIC regimens have thus
become standard of care for many patients, typically older or
with comorbidities, who nevertheless stand to beneﬁt from
allogeneic HCT.
Unfortunately, many patients who are considered for
allogeneic transplantation have poor-risk or advanced-stage
disease and, because of the high risk of relapse, may be
unsuitable for HCT with lower intensity regimens. The desire
to offer transplantation to these patients, despite older age
and compromised organ function, has prompted the search
for regimens that have signiﬁcant activity against common
hematologic cancers but are less toxic than traditionalTransplantation.
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reduced-toxicity regimens attempt to ﬁnd a balance bet-
ween tumor debulking and toxicity, an issue that is relevant
for all patients, but particularly so for patients who are
heavily pretreated, older, or who suffer from signiﬁcant
comorbidities. From an operational standpoint, the ideal
reduced-toxicity regimen should cause minimal organ
damage, result in prompt and durable donor immunologic
reconstitution, and have signiﬁcant activity against a broad
range of hematologic malignancies.
In 2008, Marks et al. [4] reported results in 133 patients
who underwent transplantation between 1998 and 2003,
and who were conditioned with a reduced-toxicity regimen
of ﬂudarabine, BCNU (carmustine, [1,3-bis(2-chloroethyl)-1-
nitrosourea]), and melphalan (FBM). Given that all patients
in that study were considered ineligible for standard ablative
conditioning, were older, and often had active disease at
transplantation, the long-term results were very favorable
(5-year event-free survival [EFS] of 42%). Based on these
encouraging data, we incorporated the FBM regimen into our
transplantation practice, and it has become 1 of our standard
reduced-intensity or reduced-toxicity regimens. To reduce
the risk of severe chronic graft-versus-host disease (GVHD),
we included rabbit antithymocyte globulin (ATG) according
to a prespeciﬁed dosing algorithm in all patients (FBM-A
conditioning). We report here transplantation outcomes in
100 adult patients who underwent allogeneic HCT using
FBM-A conditioning at our center between 2009 and 2012.
We stratiﬁed patients using the recently described disease
risk index (DRI) [5], which takes into account both disease
risk (speciﬁcally incorporating cytogenetics for patients with
myelodysplastic syndrome [MDS] and acute myelogenous
leukemia [AML]) and disease stage in formulating a compre-
hensive risk index for patients undergoing allogeneic HCT.
MATERIALS AND METHODS
Patients
This report is an institutional review boardeapproved retrospective
review of transplantation outcomes for patients who underwent trans-
plantation at Mayo Clinic Arizona (n ¼ 99) or Phoenix Children’s Hospital
(n¼ 1) between August 2009 and November 2012. Patients were considered
for the FBM-A regimen if they were  age 55 or, if <age 55, not eligible for
a fully ablative regimen because of comorbidity, active infection, or previous
autologous HCT. Consecutive patients who met the following criteria are
included in this report: (1) age between 18 and 69, (2) ﬁrst allogeneic HCT,
(3) minimum 3 months of follow-up, and (4) not in refractory relapse at the
time of HCT. A total of 12 patients had undergone prior autologous trans-
plantation (4 of 4 Hodgkin lymphoma patients, 3 of 8 non-Hodgkin
lymphoma (NHL) patients, and 5 patients who underwent transplantation
for therapy-related-MDS after autologous transplantation for breast cancer
(n ¼ 1), multiple myeloma (n ¼ 1), testicular cancer (n ¼ 1), Hodgkin
lymphoma (n ¼ 1), and NHL (n ¼ 1). Patients and prospective donors were
HLA-typed at high resolution using standardmethods; minimum acceptable
donormatchwas 6/8 at HLA-A, B, C, and DRB1 for both related and unrelated
donors. One patient received a 4/6 matched double cord graft.
Conditioning, GVHD Prophylaxis, and Supportive Care
All patients received ﬂudarabine, BCNU, and melphalan dosing as
previously published [4]. Dosing was based on the lower of ideal or actual
body weight, or adjusted ideal body weight if actual body weight exceeded
125% of ideal. The dose of ﬂudarabine was adjusted for renal insufﬁciency if
the calculated creatinine clearance was <60 mL/min. Patients older than
55 or with signiﬁcantly compromised performance status received dose
reductions of BCNU and melphalan as described [4]. GVHD prophylaxis
consisted of tacrolimus, mycophenolate mofetil (MMF), and rabbit ATG
(Thymoglobulin; Genzyme, Cambridge, MA). The dose of ATG ranged from
2.5 mg/kg to 7.5 mg/kg given over 1 to 3 days as follows: patients with no
mismatch received 2.5 mg/kg on day1, patients with 1 (allele or antigenic)
mismatch received 2.5 mg/kg for 2 doses on days 2 and 1, and patients
with 2 (allele or antigenic) mismatches received 2.5 mg/kg for 3 doses on
days 3, 2, and -1. Methotrexate was substituted for MMF in 4 patients inthe later stages of the reporting period because of excess rates of gastroin-
testinal acute GVHD observed in the MMF patients. Stem cells were infused
on day 0 (median CD34 dose, 6.1 x 106/kg [range, 1.7 to 19]; median CD3
dose, 2.7 x 108/kg [range, .14 to 5.8]). All patients were monitored weekly or
twice weekly using quantitative PCR for evidence of cytomegalovirus (CMV)
or Epstein-Barr virus (EBV) reactivation; patients who tested positive for
CMV were treated with pre-emptive ganciclovir or foscarnet, and patients
with evidence of EBV reactivation received from 1 to 4 doses of rituximab
(375 mg/m2 per dose). All other supportive care was provided according to
standard operating procedures developed by our program.
GVHD Grading and Treatment, and Posttransplantation Follow-Up
Acute and chronic GVHD were graded using consensus criteria [6] and
National Institutes of Health (NIH) criteria [7]. For GVHD grading, patients
were censored at the time of relapse/disease progression, as such patients
underwent accelerated withdrawal of immune suppression or donor
lymphocyte infusion to induce GVHD (no patient received donor lympho-
cyte infusion for graft failure). All patients were monitored for engraftment
and chimerism status at routine intervals after transplantation (generally,
months 1, 2, 3, 6, and 12). Peripheral blood was sorted into CD3 and CD33
fractions and analyzed for the percentage of donor and recipient cells using
standard techniques. Disease assessments were performed at 3, 6, 9, and
12 months after transplantation, and thereafter at the discretion of the
attending physician. Pulmonary function testing was performed before
transplantation and, in most patients, at 3, 6, and 12 months after
transplantation.
Deﬁnitions and Statistical Methods
The primary aims of this study were to (1) evaluate the safety, tolera-
bility, and efﬁcacy of the FBM-A regimen in adult patients with hematologic
malignancy; (2) assess the impact of patient characteristics, comorbidities,
and DRI on HCT outcomes; and (3) determine the impact of ATG on the
incidence and severity of acute and chronic GVHD. For acute leukemia
patients, complete remission was deﬁned based on standard criteria [8];
therefore, patients with incomplete count recovery or persistent dysplasia
in the bone marrow after treatment, regardless of blast percentage, were
considered not in complete remission at HCT, as were patients who
underwent HCT in aplasia.
Univariate probabilities of overall survival (OS) and EFS were estimated
using the Kaplan-Meier method [9]. For EFS, relevant events were death,
disease relapse/progression, or second transplantation. Cause of death was
considered due to relapse/disease progression regardless of subsequent
events after diagnosis of relapse. GVHD was considered the cause of death if
a patient was under active treatment for active GVHD and succumbed to
complications related to such treatment (eg, infection or organ failure).
Probabilities of relapse, nonrelapse mortality (NRM), and GVHD were
calculated using the cumulative incidence procedure to accommodate
competing risks. For acute and chronic GVHD, relapse and NRM were
considered competing risks. The following variables were analyzed in
univariate and multivariate regression analysis to identify factors that
inﬂuenced outcome: age (<55 versus 55), DRI (low/intermediate versus
high/very high), HCT-comorbidity index (HCT-CI, 0 to 2 versus 3) donor
type (related versus unrelated), HLA match (8/8 match versus 7/8 or 6/8
match), donor-recipient sex match (female donor/male recipient versus
all other combinations), and CMV serostatus (patient/donor negative/nega-
tive versus all other combinations). Cox proportional hazards regressionwas
used for OS and EFS, whereas Fine-Gray proportional subdistribution hazards
regression was used for outcomes with competing risks. All statistical anal-
yses were performed using SAS v9.2 software (SAS institute, Cary, NC).
RESULTS
Patient and Transplantation Characteristics
One hundred patients, median age 56 (range, 23 to 69)
underwent allogeneic HCT using FBM-A conditioning
between August 2009 and November 2012; 29 patients were
60 years of age at the time of transplantation. The indica-
tion for allogeneic HCT in all patients was high-risk hema-
tologic malignancy; Table 1 presents the diagnoses and risk
features of the patients included in this study. Disease risk at
transplantation, according to the DRI was low in 1, inter-
mediate in 67, high in 28, and very high in 4 (Table 2).
Because of the low numbers of patients in the low and very
high risk groups, for subsequent analyses, the low and
intermediate groups were combined (total, 68 patients), as
were the high and very high (VH) risk groups (total, 32
Table 1
Patient Diagnoses and Risk Factors
Diagnoses and Risk Factors No. of Patients
(N ¼ 100)
AML (n) 40
Age, median yr (range) 56 (23 to 69)
AML type, n (%)
de-novo 23 (58%)
Therapy-related 7 (17%)
Secondary* 10 (25%)
Cytogenetics, n (%)
Good 2 (5%)
Intermediate-normaly 15 (38%)
Intermediate-other 6 (15%)
Adverse 17 (43%
Monosomal karyotypez 8 (20%)
Status at transplantation, n (%)
CR1 18 (45%)
CR2 7 (18%)
Not in CR (blasts < 5%) 8 (20%)
Aplasia 7 (18%)
MDS (n) 24
Age, median yr (range) 56.5 (34 to 66)
MDS type, n (%)
de-novo 14 (58%)
Therapy-related 9 (38%)
Evolved from aplastic anemia 1 (4%)
Cytogenetics, n (%)x
Not adverse 15 (63%)
Adverse 9 (37%)
Status at transplantation, n (%)
Blasts < 5% 17 (71%)
Blasts 5% to 9% 5 (21%)
Blasts 10% to 19% 2 (8%)
Pretransplantation therapy, n (%)
Untreated 5 (21%)
Hypomethylating agent 15 (63%)
Chemotherapy 3 (13%)
Lenalidomide 1 (4%)
ALL (n) 8
Age, median yr (range) 54.5 (33 to 66)
Status at Transplantation, n (%)
CR1 6 (75%)
CR2 1 (13%)
Not in CR (blasts < 5%) 1 (13%)
Cytogenetics, n (%)
Normal 3 (38%)
t(9;22) 4 (50%)
Other 1 (13%)
Myeloﬁbrosis (n) 13
Age, median yr (range) 60 (47 to 68)
Type myeloﬁbrosis, n (%)
Primary 7 (54%)
Secondary (P. vera) 4 (31%)
Secondary (ET) 2 (16%)
DIPSS-plus risk group, n (%)
Int-1 1 (8%)
Int-2 5 (39%)
High 7 (54%)
JAK-2 status
Positive 7 (54%)
Negative 6 (46%)
Lymphoma (n) 12
Age, median yr (range) 38 (23 to 62)
Lymphoma subtype
Hodgkin, n (%)k 4 (33%)
Non-Hodgkin, n (%) 8 (67%)
B cell DLCL, n{ 4
Mantle cell, n 1
NHL T/NK (nodal), n 2
NHL T/NK (extra-nodal), n 1
AML indicates acute myelogenous leukemia; CR1, ﬁrst complete remission;
CR2, second complete remission; MDS, myelodysplastic syndrome; ALL,
acute lymphoblastic leukemia; P. vera, polycythemia vera; ET, essential
thrombocythemia; DIPSS, Dynamic International Prognostic Scoring
System; NHL, non-Hodgkin lymphoma; DLCL, diffuse large cell lymphoma;
T/NK, T cell and natural killer.
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Seventy-four patients (74%) underwent transplantation from
unrelated donors (73 adult volunteer donors and 1 unrelated
double cord); among the 74 unrelated donor products,
almost one-half (n ¼ 33, 45%) were mismatched (1-locus
mismatch, n ¼ 24; 2-locus mismatch, n ¼ 9). Forty-three
patients had an HCT-CI [10] score of 3.
Engraftment and Chimerism
All patients achieved hematologic recovery with absolute
neutrophil count of 500/microliter, with no cases of
primary graft failure or rejection. For patients with adequate
numbers of CD3 cells to evaluate T cell chimerism status,
79 of 79 patients assayed at day 28 were 100% donor. Overall,
96 patients had at least 1 determination that was 100% donor
CD3. Among the 4 patients for whom 100% donor CD3
chimerism has not been documented, 1 patient relapsed
early, and 1 patient has had 2 noninformative assays at 1 and
2 months after transplantation. The other 2 patients have
been treated for prolonged CMV viremia and have yet to
achieve full donor CD3 engraftment. Four patients have
demonstrated partial loss of donor lymphoid cells after
initial attainment of 100% donor CD3 chimerism; 1 patient
subsequently relapsed, whereas 3 remain in continuous
remissionwith CD3 chimerismvalues of 90%, 80%, and 40% at
1 year after HCT.
Survival
At the time of this analysis, 80 patients are alive, with
a median follow up of 17.5 months (range, 3 to 41.5).
Univariate probabilities of outcome for all patients and by
DRI are shown in Table 3. The Kaplan-Meier estimate of
overall survival for all patients at 1 and 2 years was 85% (95%
conﬁdence interval [CI], 76% to 91%) and 76% (95% CI, 65% to
84%), respectively (Figure 1A); corresponding rates of EFS
were 79% (95% CI, 69% to 86%) and 76% (95% CI, 66% to 84%).
Overall survival for patients classiﬁed as DRI low/interme-
diate was 87% (95% CI, 76% to 94%) at 1 year and 80% (95% CI,
67% to 89%) at 2 years, versus 80% (95% CI, 61% to 91%) and
66% (95% CI, 44% to 81%) for DRI high/VH patients (Figure 1B;
P ¼ .11). A similar difference was seen in EFS for the 2 risk
groups (Table 3 and Figure 1C; P ¼ .14). In Cox regression
analysis (Table 4), there was a statistically nonsigniﬁcant
trend for improved OS and EFS in the DRI low/intermediate
compared with high/VH patients (for OS, hazard ratio [HR],
.51; 95% CI, .18 to 1.42); P¼ .20; for EFS, HR, .59 [95% CI, .22 to
1.62]; P ¼ .31). Survival was not inﬂuenced by age at trans-
plantation (<55 versus 55), HCT-CI (0 to 2 versus 3),
donor type (related versus unrelated), HLA mismatch (no [8/
8] versus yes [6/8 or 7/8]), or sex match (female donor to
male recipient versus all other combinations). There was
a trend for improved OS and EFS in the CMV negative/
negative patient group, compared with all other CMV
combinations (Table 4).The table does not include 2 patients who underwent transplantation for
other myeloid malignancies (systemic mastocytosis and chronic neutro-
philic leukemia, 1 each), and 1 patient who underwent transplantation for
chronic lymphocytic leukemia.
* Evolved from MDS (n ¼ 8) or from myeloproliferative disease (n ¼ 2).
y FLT3-ITD positive (n ¼ 3), not tested (n ¼ 4), negative (n ¼ 8).
z Breems et al. [11].
x Cytogenetics classiﬁed according to Armand et al. [12].
k All 4 with previous autologous stem cell transplantation.
{ Three had undergone previous autologous stem cell transplantation.
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76% (65 to 84) at 2 years
DRI Low/Int: 80% (67 to 89)
DRI High/VH: 66% (44 to 81)
DRI Low/Int: 80% (67 to 88)
DRI High/VH: 69% (48 to 83)
Table 2
Transplantation Characteristics
Characteristic No.
Disease risk index*
Low 1
Intermediate 67
High 28
Very high 4
Donor and HLA match
Related, matched (8/8) 22
Unrelated, matched (8/8) 41
Related, mismatchedy 4
Unrelated, mismatchedz 33
GVHD prophylaxis
Tacrolimus, MMF, ATG 96
Tacrolimus, MTX, ATG 4
ATG dose
2.5 mg/kg 64
5.0 mg/kg 27
7.5 mg/kg 9
CMV status
Recipient negative/donor negative 15
All other combinations 85
Sex match
Female donor/male recipient 24
All other combinations 76
Graft source
PBSC 97
Bone marrow 2
Umbilical cord blood 1
HCT-CI
0 to 2 57
3 43
HLA indicates human leukocyte antigen; GVHD, graft-versus-host disease;
MMF, mycophenolate mofetil; MTX, methotrexate; CMV, cytomegalovirus;
PBSC, peripheral blood stem cells; HCT-CI, hematopoietic cell
transplantation-comorbidity index.
* As deﬁned by Armand et al. [5].
y One antigen mismatch at A (n ¼ 3), 1 antigen mismatch at DRB1 (n ¼ 1).
z One antigen/allele mismatch at A (n ¼ 11), B (n ¼ 6), C (n ¼ 4), or DRB1
(n ¼ 3). Two-locus mismatches as follows: A antigen þ A allele (n ¼ 1); A
antigen þ B antigen (n ¼ 1); B antigen/allele þ C antigen/allele (n ¼ 7).
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The cumulative incidence of NRM for all patients at
100 days, 1 year, and 2 years was 4.1% (95% CI, 1.8% to 9.0%),
11% (95% CI, 6.1% to 18%) and 16% (95% CI, 9.5% to 27%),
respectively (Table 3). There was a trend for lower NRM in
patients with lower HCT-CI scores (0 to 2 versus 3) (HR, .38Table 3
Univariate Probabilities of Outcome, All Patients and by Disease Risk Index
Outcome Event All Patients
(N ¼ 100)
DRI Low/Int
(n ¼ 68)
DRI High/VH
(n ¼ 32)
P
Probability
(95% CI)
Probability
(95% CI)
Probability
(95% CI)
Overall survival .11
1-yr 85 (76 to 91) 87 (76 to 94) 80 (61 to 91)
2-yrs 76 (65 to 84) 80 (67 to 89) 66 (44 to 81)
Event-free survival .14
1-yr 79 (69 to 86) 84 (72 to 91) 69 (48 to 83)
2-yrs 76 (66 to 84) 80 (67 to 88) 69 (48 to 83)
Nonrelapse
mortality
.81
100-days 4.1 (1.8 to 9.0) 3.6 (1.3 to 9.9) 5.0 (1.4 to 17)
1-yr 11 (6.1 to 18) 9.9 (5.0 to 19) 13 (4.8 to 29)
2-yrs 16 (9.5 to 27) 15 (7.8 to 28) 19 (7.0 to 42)
Relapse .07
1-yr 7.4 (3.8 to 14) 3.6 (1.2 to 11) 15 (6.4 to 32)
2-yrs 14 (7.2 to 25) 9.9 (3.7 to 24) 25 (10 to 48)
VH indicates very high.
Figure 1. Kaplan-Meier survival estimates. Overall survival for all patients (A)
and stratiﬁed by disease risk index (B). Event-free survival stratiﬁed by disease
risk index is shown in (C). Estimated 2-year survivals for each group are
shown, with univariate P values.[95% CI, .12 to 1.22]; P ¼ .10); patients who underwent
transplantation from an unrelated donor had a trend for
higher risk of NRM compared with related donors (risk ratio,
4.28 [95% CI, .58 to 31.8; P ¼ .16]). There was no discernible
impact on NRM of age, HLA mismatch, disease risk index,
donor gender, or CMV status (Table 4).
Relapse
At the time of this analysis, there have been 9 patients
who have relapsed (7 AML, 1 MDS, 1 acute lymphoblastic
leukemia), of whom 8 have died; the median time to relapse
was 266 days (range, 56 to 475), with 2 relapses occurring
1 year post-HCT. There have been no relapses among
the 13 patients who underwent transplantation for myelo-
ﬁbrosis (median follow-up, 12 months; range, 5 to 27), and
no relapses among 13 patients underwent transplantation
Table 4
Cox Proportional Hazards Analysis
Category Comparison Overall Survival Event-Free Survival NRM Relapse
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age <55 vs. 55 .95 .38 to 2.34 .90 1.07 .44 to 2.61 .88 .58 .17 to 2.00 .39 1.86 .36 to 9.75 .46
Disease risk index Low/intermediate vs. high/VH .51 .18 to 1.42 .20 .59 .22 to 1.62 .31 1.35 .40 to 4.65 .63 .20 .02 to 1.38 .10
HCT-CI 0 to 2 vs. 3 .70 .28 to 1.75 .44 .63 .26 to 1.56 .32 .38 .12 to 1.22 .10 1.19 .26 to 5.36 .82
Donor Unrelated vs. related .83 .26 to 2.65 .75 .89 .28 to 2.83 .84 4.28 .58 to 31.8 .16 .22 .04 to 1.28 .09
Mismatch No vs. yes .74 .28 to 1.95 .55 .69 .27 to 1.75 .43 .87 .27 to 2.74 .81 .50 .17 to 1.53 .23
Sex match Female donor/male recipient vs. others 1.03 .30 to 3.52 .96 .90 .27 to 3.01 .87 .65 .15 to 2.91 .58 1.73 .27 to 11.2 .56
CMV status Neg/neg vs. others .42 .09 to 1.87 .25 .37 .08 to 1.67 .20 .31 .04 to 2.28 .25 .61 .06 to 6.1 .67
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Figure 2. Cumulative incidence of relapse for all patients (A), stratiﬁed
by disease risk index (B), and for patients with related vs. unrelated donors (C).
Estimated 2-year relapse rates are shown, with univariate P values.
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leukemia (median follow-up, 16 months; range 5 to 30). For
all patients, the cumulative incidence of relapse was 7.4%
(95% CI, 3.8% to 14%) at 1 year, and 14% (95% CI, 7.2% to 25%)
at 2 years (Table 3; Figure 2A). For patients in the low/
intermediate risk group, the relapse incidence was 3.6% (95%
CI, 1.2% to 11%) at 1 year and 9.9% (95% CI, 3.7% to 24%) at
2 years, compared with 15% (95% CI, 6.4% to 32%) and 25%
(95% CI, 10% to 48%) in the high/VH risk group (univariate P¼
.07; Figure 2B). In Cox regression analysis, relapse risk was
inﬂuenced by disease risk index (HR, .20 [95% CI, .02 to 1.38];
P ¼ .10, low/intermediate versus high/VH risk) and donor
type (unrelated versus related donor; HR, .22 [95% CI, .04
to 1.28]; P ¼ .09; Figure 2C), but not by age, HCT-CI,
HLA mismatch, or sex match. No patient in the CMV nega-
tive/negative group has relapsed. One AML patient is alive
after relapse, approximately 1 year after salvage chemo-
therapy and a second allogeneic HCT from a different
unrelated donor.
GVHD
Acute GVHD
The cumulative incidence of acute GVHD grades II to IV at
day 100 and 6 months was 39% (95% CI, 31% to 47%) and 51%
(95% CI, 42% to 60%), respectively. The incidence of acute
GVHD grades III to IV was 8.1% (95% CI, 4.2% to 12%) at
100 days and 11% (95% CI, 6.4% to 18%) at 6 months
(Figure 3A). The rate of acute GVHD was not inﬂuenced by
age, donor type, or patient/donor sex match. Among the
74 unrelated donor transplantations, the incidence of grades
III to IV acute GVHD was not signiﬁcantly different between
matched (8/8) and mismatched (6/8 and 7/8) trans-
plantations (Figure 3B); however, only 2 of 33 patients
undergoing mismatched unrelated HCT have developed
grades III to IV acute GVHD. Overall, 13 patients developed
severe (grades III to IV) acute GVHD; the median day of onset
was 29 (range, 10 to 223, with 2 cases occurring after
6 months); the severe grade was due to stage 3 or 4 GI GVHD
in all cases (4 patients in addition had liver stage 2, and
3 patients had skin stage 3).
Chronic GVHD
A total of 17 patients developed signs or symptoms
compatible with a diagnosis of chronic GVHD per NIH deﬁ-
nitions [7]. Among these 17 patients, 6 were graded as mild,
7 moderate, and 4 severe. The cumulative incidence of NIH-
deﬁned moderate to severe chronic GVHD was 8.8% (95% CI,
4.7% to 16%) at 1 year and 22% (95% CI, 12% to 35%) at 2 years
(Figure 3C); the corresponding incidence of severe chronic
GVHD was 2.2% (95% CI, .6% to 7.6%) and 8.3% (95% CI, 3.1% to
21%) at 1 and 2 years, respectively. In Cox regression analysis,
no factor was found to signiﬁcantly inﬂuence thedevelopment of moderate to severe chronic GVHD. To date,
no patient has died from chronic GVHD or complications
thereof.
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Figure 3. Cumulative incidence of acute GVHD grades III to IV for all patients
(A), and for patients receiving transplantations from unrelated donors strati-
ﬁed by HLA match (B). Cumulative incidence of NIH-deﬁned moderate to
severe chronic GVHD for all patients (C).
Table 5
Regimen-Related Toxicity
Grade Renal Pulmonary Hepatic Cardiac CNS
II 15 2 3 5 0
III 1 2 0 0 2
IV 0 0 0 0 0
CNS indicates central nervous system.
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Sixty-four patients underwent transplantation for MDS
(n ¼ 24) or AML (n ¼ 40). Among the 40 patients with AML,
17 cases were secondary (either therapy-related or evolved
from a previous myeloid disorder), 17 had an adverse
karyotype (including 8 with a monosomal karyotype [11]),
and 22 underwent transplantations beyond ﬁrst complete
remission (Table 1). Among the 24 MDS cases, 9 (38%) were
therapy-related, 9 had an adverse karyotype as deﬁned by
Armand et al. [12], and 7 had >5% marrow or blood blasts
pretransplantation. At 1 and 2 years, the OS for the entire
group of patients is estimated at 82% (95% CI, 69% to 90%) and
71% (95% CI, 56% to 81%), respectively. At 2 years, the EFS,
stratiﬁed by DRI, was 70% (95% CI, 51% to 83%) for the DRI
low/intermediate group, versus 62% (95% CI, 39% to 80%) for
the DRI high/VH patients (P ¼ .54).Toxicity and Adverse Events
Organ toxicity
According the regimen-related toxicity (RRT) index pub-
lished by Bearman et al. [13], there were 5 cases of grade III
RRT (1 renal, 2 pulmonary, and 2 central nervous system;
Table 5). Transient elevations of serum creatinine (>2 times
baseline, grade II) were seen in 15 patients. Other grade II
toxicities included pulmonary (n ¼ 2), hepatic (n ¼ 3), and
cardiac (n ¼ 5). No deaths were recorded before day 28. At
the time of analysis, 12 patients have died of nonrelapse
causes: 6 from GVHD or complications of its treatment,
3 from multiorgan failure, 2 from infection, and 1 because
of complications of EBV-related posttransplantation lym-
phoproliferative disorder (EBV-PTLD). There were 4 cases
of presumed BCNU-related pneumonitis (2 grade II, 2 grade
III); all 4 patients responded to corticosteroids and are
without long-term pulmonary dysfunction. To detect more
subtle decrements in lung function, pulmonary function
testing was performed before transplantation and at 3, 6, and
12 months after transplantation. There was no signiﬁcant
change in forced expiratory volume in 1 second through
1 year after transplantation. However, there was a modest
decline in carbon monoxide diffusing capacity corrected for
hemoglobin (DLCOC) at 3, 6, and 12 months after trans-
plantation (median DLCOC pretransplantation, 87% of pre-
dicted versus 72%, 71%, and 73% at 3, 6, and 12 months,
respectively). No patient has developed bronchiolitis oblit-
erans, and no patient has died of late noninfectious pulmo-
nary toxicity.
Infections
Two patients died of infection without concurrent GVHD
(1 due to pulmonary aspergillus, and 1 due to multidrug-
resistant CMV pneumonia). In 5 additional patients with
severe GVHD, infection was a contributing factor to their
death. The cumulative incidence of CMV reactivation at
6 months was 47% (95% CI, 39% to 56%), with a median time
to reactivation of 32 days (range, 3 to 380). CMV disease
developed in 21 patients (enteritis [n ¼ 8], pneumonitis
[n ¼ 7], multiorgan [n ¼ 5], and isolated retinitis [n ¼ 1]).
Infection with or reactivation of other viruses (BK, RSV,
HHV6, inﬂuenza, parainﬂuenza) was common, but did not
directly contribute to the death of any patient.
EBV reactivation and EBV-PTLD
The incidence of EBV reactivation, deﬁned as a persistent
or increasing quantitative PCR value > 2000 copies/mL,
was 25% (95% CI, 17% to 34%) at 1 year. The median day of
reactivation was 52 (range, 27 to 624), and the median
maximum copy number was 8460 (2000 to 172,000). Among
the 25 patients who reactivated EBV, 24 were treated with
Rituxan, with clearance of EBV DNA from the blood in all
patients (1 patient cleared spontaneously). There were
4 cases of EBV-PTLD, 2 of which occurred late (days þ232
and þ344) and without documented evidence of prior EBV
reactivation. One of these patients died of respiratory failure,
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for EBV-PTLD; this patient’s death was considered secondary
to EBV-PTLD. The additional 3 patients were treated
successfully with single-agent Rituxan. The 2 cases of early
EBV-PTLD (days þ54 and þ85) were preceded by EBV reac-
tivation in the blood at days þ38 and þ76, respectively.
DISCUSSION
This study presents outcome data on a large, uniformly
treated population of adult patients with high-risk hemato-
logic malignancy conditioned with a reduced toxicity
regimen of ﬂudarabine, BCNU, melphalan, and ATG (FBM-A).
Although patients were older (median age 56; 29% 60), and
often had high comorbidity scores (43 patients with HCT-CI
 3), the NRM was modest (11% at 1 year), and outcomes
were satisfactory (OS, 76% at 2 years). The FBM (A) regimen
was originally proposed as an option for older or heavily
pretreated patients with refractory or advanced hematologic
malignancies [4]. In agreement with Marks et al., we
observed low rates of severe regimen-related toxicity (only
5 patients with grade III RRT, all reversible) compared to
conventional total body irradiation (TBI)- or busulfan-based
ablative regimens. Overall survival in our patient cohort
was not signiﬁcantly inﬂuenced by age (<55 versus 55)
or HCT-CI (0 to 2 versus 3), suggesting that the FBM-A
regimen is a suitable choice for patients at least up to age
69, as well as for patients with higher comorbidity scores.
However, it should be cautioned that the patients in this
study generally had good performance status (no patient had
Karnofsky Performance Status <70), and only 29 patients
had an HCT-CI score  4. Although considered “reduced
toxicity” and technically meeting criteria for a RIC regimen
[14,15], the FBM-A regimen caused universal myelosup-
pression followed by early and generally durable complete
donor myeloid and lymphoid chimerism. These features
suggest that FBM-A is, operationally, fully myeloablative.
Outcomes for patients in this study were inﬂuenced
mainly by disease risk before transplantation, using either
Center for International Blood and Marrow Transplantation
Researchedeﬁned risk classiﬁcations (data not shown) or the
DRI recently described by Armand et al. [5]. The DRIdwhich,
in addition to disease type and stage, takes into account
cytogenetics in patients with MDS and AML [12,16]dwas
able to stratify patients in this study into 2 groups with
somewhat different outcomes. For patients with low or
intermediate risk, according to the DRI, the estimate of OS at
2 years was 80%, which is very encouraging given the older
patient population and the large number of mismatched
related and unrelated donors. Outcomes for patients with
high or VH risk according to the DRI (2-year survival, 66%)
were somewhat poorer, as expected, but nevertheless
encouraging in a patient group with very high risk features
before allogeneic HCT. Among the 40 AML patients in this
study, 15 were not in remission at the time of transplantation
(7 patients underwent transplantation in aplasia and
8 additional patients with either incomplete count recovery
or residual dysplastic changes in the bone marrow). The
2-year OS for the AML patients in complete remission was
80%, versus 44% for the 15 patients not in remission (P¼ .05).
It is notable that 4 of the 7 patients with refractory AML who
underwent transplantation in aplasia (after cytoreduction
with clofarabine) are long-term survivors.
The ideal conditioning regimen before allogeneic
HCT has not been established [17,18], and it is not clear, at
least in patients without active or refractory disease attransplantation, whether conditioning intensity even mat-
ters. Only 1 randomized trial of RIC versus standard ablative
conditioning has been published [19]; that trialdwhich was
closed early because of poor accrualdcompared ﬂudarabine
plus lower dose TBI (800 cGy) to conventional cyclophos-
phamide/TBI (1200 cGy), and found no difference in OS. For
patients who are not considered candidates for conventional
ablative regimens, the issue becomes how to balance dose
intensity with toxicity, and how to maximize the graft-
versus-malignancy effect. There is compelling evidence
that dose intensity is still needed to ensure optimal outcome
after allogeneic HCT [17], and healthy patients, at least up to
age 65, are nowcommonly offered reduced toxicity regimens
using intravenous busulfan (at full myeloablative doses) with
either ﬂudarabine (Bu-Flu) or cyclophosphamide (Bu-Cy).
These regimens are safe and effective, and extend dose
intensity to older patients who have historically not been
considered candidates for allogeneic HCT [20].
Where does FBM-A ﬁt in the context of other reduced-
toxicity regimens, and are there patient populations that
may speciﬁcally beneﬁt from FBM-A as opposed to higher
intensity regimens, such as Bu-Flu or Bu-Cy? Although the
answer to this question is unclear, a retrospective compar-
ison, using data from our program, between melphalan-
based RIC regimens (FBM, n ¼ 116; Flu-Mel, n ¼ 17) and
Bu-based myeloablative regimens (Flu-Bu, n ¼ 18; Bu-Cy,
n ¼ 54; both þ/ ATG) in similar patient groups and over
a similar time period showed no difference in any major
outcome, although the melphalan-based RIC patients were
older, had higher HCT-CI scores, andmore often received ATG
(data not shown). It is thus very likely that disease biology
and stage (as suggested by the DRI) have much more inﬂu-
ence on outcome after allogeneic HCT than regimen choice
(at least considering the commonly used regimens discussed
above). In this study, outcomes for patients with myeloﬁ-
brosis (n ¼ 13; median age, 60) were promising, with all
patients alive in remission at a median follow-up of
12 months. Furthermore, among 21 patients with lymphoid
malignancies, 17 remain alive with a median follow-up of
16 months, with only 1 relapse to date in a patient with
Teacute lymphoblastic leukemia. Although longer follow-up
will be required, the preliminary data suggest that FBM-A
may be particularly effective and suitable for myeloﬁbrosis
patients (up to age at least 69) and for patients with
lymphoid malignancies who are in complete remission or
partial remission at the time of allogeneic HCT.
The addition of ATG to the FBM backbone proved safe,
without excess early toxicity and manageable rates of
opportunistic infection. Despite a high percentage of unre-
lated and mismatched donors, the incidence of severe acute
GVHD was modest, and rates of moderate to severe chronic
GVHD were low. Taking into account the risk status of the
patients in this study, the relapse rate did not appear
excessive, and was not different from similar, contempora-
neous patients treated without ATG in our practice (data not
shown). Acknowledging the considerable controversy
regarding the overall beneﬁt of in vivo T cell depletion
[21,22,23,24], particularly in the setting of RIC, we believe
that the risk to beneﬁt ratio favors the use of ATG in patients
conditioned with FBM who have clinical characteristics
similar to those reported here.
In summary, our results show that the FBM-A regimen is
safe, well tolerated, and effective in ﬁt patients up to age 69
with a wide array of hematologic malignancies. As expected,
outcomes were best in lower-risk patients based on disease
J.L. Slack et al. / Biol Blood Marrow Transplant 19 (2013) 1167e11741174type or stage, but factors such as age, comorbidity score, and
donor type seemed to have minimal inﬂuence on outcome.
Curative strategies for very advanced, refractory, or higher-
risk hematologic malignancies will likely require additional
pre- or posttransplantation approaches to reduce disease
burden or eradicate minimal residual disease, respectively.
The FBM-A regimen offers a safe and effective platform to
investigate such approaches.ACKNOWLEDGMENTS
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